Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr Al-Aini street, Cairo, 11562, Egypt.
Pharmacology Department, National Research Centre, 33 El-Buhouth street, Dokki, Giza, 12622, Egypt.
Naunyn Schmiedebergs Arch Pharmacol. 2019 Dec;392(12):1605-1616. doi: 10.1007/s00210-019-01699-y. Epub 2019 Aug 1.
Despite the availability of effective antiulcer medications, their suboptimal safety profile ignites the search for alternative/complementary treatments. Drug repositioning is an attractive, efficient, and low-risk strategy. Cilostazol, a clinically used phosphodiesterase 3 inhibitor, has pronounced anti-inflammatory and vasodilatory effects suggesting antiulcer activity. Using ethanol-induced and pyloric ligation-induced gastric ulcer models, we investigated the gastroprotective effect of cilostazol (5 or 10 mg/kg, p.o.) in comparison with the standard antiulcer ranitidine (50 mg/kg, p.o.) in rats. Gastric mucosa was examined macroscopically, histologically, and biochemically for ulcer severity, markers of oxidative stress, proinflammatory cytokines, apoptotic, and cytoprotective mediators. Gastric acidic output, peptic activity, and mucin content were measured in gastric fluids. Pretreatment with cilostazol reduced ulcer number and severity, ameliorated redox status (reduced glutathione and malonaldehyde content), and decreased levels of IL-1β, IL-6, and TNF-훼 in gastric mucosa, in parallel with increases in mucosal defensive factors nitric oxide (NO), prostaglandin E (PGE), and heat-shock protein 70 (HSP70) promoting mucus secretion, tissue perfusion, and regeneration. Histological examination confirmed the beneficial effects of cilostazol in terms of reducing focal necrosis and infiltration of inflammatory cells, as well as increasing mucopolysaccharide content. These beneficial effects are likely secondary to an increase in cAMP and decrease in apoptosis regulator Bcl-2-associated X protein (BAX). Cilostazol, in a dose-dependent effect, exhibited vasodilatory, anti-inflammatory, and antiapoptotic actions in the gastric mucosa resulting in significant antiulcer activity comparable with the standard drug, ranitidine, but devoid of antisecretory activity. Therefore, its use should be dose and ulcer-inducer dependent.
尽管有有效的抗溃疡药物,但它们不理想的安全性促使人们寻找替代/补充治疗方法。药物重定位是一种有吸引力、高效且低风险的策略。西洛他唑,一种临床使用的磷酸二酯酶 3 抑制剂,具有明显的抗炎和血管舒张作用,提示具有抗溃疡活性。我们使用乙醇诱导和幽门结扎诱导的胃溃疡模型,研究了西洛他唑(5 或 10mg/kg,po)与标准抗溃疡雷尼替丁(50mg/kg,po)在大鼠中的胃保护作用。通过宏观、组织学和生化方法检查胃黏膜的溃疡严重程度、氧化应激标志物、促炎细胞因子、凋亡和细胞保护介质。测量胃液中的胃酸分泌、胃蛋白酶活性和粘蛋白含量。西洛他唑预处理可减少溃疡数量和严重程度,改善氧化还原状态(还原型谷胱甘肽和丙二醛含量降低),降低胃黏膜中白细胞介素 1β、白细胞介素 6 和肿瘤坏死因子-α的水平,同时增加黏膜防御因子一氧化氮(NO)、前列腺素 E(PGE)和热休克蛋白 70(HSP70),促进黏液分泌、组织灌注和再生。组织学检查证实了西洛他唑在减少局灶性坏死和炎症细胞浸润以及增加粘多糖含量方面的有益作用。这些有益作用可能是由于 cAMP 增加和凋亡调节蛋白 Bcl-2 相关 X 蛋白(BAX)减少所致。西洛他唑在胃黏膜中表现出剂量依赖性的血管舒张、抗炎和抗凋亡作用,导致与标准药物雷尼替丁相当的显著抗溃疡活性,但无抗分泌作用。因此,其使用应取决于剂量和溃疡诱导剂。